home / stock / ocgn / ocgn news

OCGN News and Press, Ocugen, Inc. From 03/01/26

Stock Information
Company Name: Ocugen, Inc.
Stock Symbol: OCGN
Market: NASDAQ
Website: ocugen.com
Menu
OCGN OCGN Quote OCGN Short OCGN News OCGN Articles OCGN Message Board
Get OCGN Alerts

News, Short Squeeze, Breakout and More Instantly...
OCGN - Earnings week ahead: AVGO, CRWD, PLUG, COST, TGT, MRVL, JD, KR, and more

2026-03-01 08:07:29 ET More on related stocks: Buy CrowdStrike As Trust Is Key In The Age Of AI Agents Costco's 2x P/E Over Amazon Is Not Irrational (Rating Upgrade) Broadcom Q1 Preview: Tech Rotation Could Trigger Another Irrational Selloff Costco is called ...
OCGN - Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results

MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s fourth quarter and ...

OCGN - Top small-cap healthcare stocks surging above 200-day moving average

2026-02-11 14:37:53 ET More on healthcare stocks Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More Viemed Healthcare: Remaining Bullish On Keen Valuation And Buoyant Cash Flow CMS Rates Proposal Shatters Health Insurance Stocks: Wh...

OCGN - Ocugen taps Rita Johnson-Greene as CFO

2026-02-09 07:07:53 ET More on Ocugen Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript Ocugen: Maintaining 'Buy' Rating On Positi...
OCGN - Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). “Mrs. Johnson-Greene&#...

OCGN - Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced underwritten registered direct offering of 15,000,000 shares of its common stock at an o...

OCGN - Ocugen prices $22.5M common stock offering at $1.50 per share

2026-01-21 08:51:04 ET More on Ocugen Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript Ocugen: Maintaining 'Buy' Rating On Positi...
OCGN - Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

MALVERN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the pricing of its underwritten offering of 15,000,000 shares of its common stock at an offering price of $1.50 per share of com...

OCGN - Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data

2026-01-16 12:28:55 ET The share price of Malvern, Pennsylvania based Ocugen, Inc. ( OCGN ), a biotech specialising in developing gene therapies to treat eye diseases, fell by nearly 15% in trading yesterday, after the company shared data from a Phase 2 clinical study eval...

OCGN - Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript

2026-01-15 14:16:03 ET Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy January 15, 2026 8:30 AM EST... Read the full article on Seeking Alpha For further details see: Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaD...
Previous 10 Next 10